论文部分内容阅读
目的评价7岁以下儿童接种1剂次或2剂次Salk株脊髓灰质炎灭活疫苗(Salk-IPV)的免疫效果,为实施灭活脊髓灰质炎疫苗(IPV)序贯免疫时制定相应的免疫程序提供参考。方法通过检索美国国家医学图书馆数据库(NCBI)、Cochrane协作网图书馆、中国生物医学文献数据库(CBMdisc)、知网数据库(CNKI)和万方数据库,将评价Salk-IPV免疫效果的研究纳入分析。以<7岁儿童接种疫苗至少1个月后诱导中和抗体的血清阳转率(SR)作为观察指标进行Meta分析;描述接种不同剂次Salk-IPV接种后血清型脊髓灰质炎中和抗体的SR的变化趋势。结果共纳入11篇文献,Meta分析结果显示:接种1剂次Salk-IPV后,I、Ⅱ和Ⅲ型脊髓灰质炎病毒中和抗体的SR分别为29%(95%CI:19%~39%)、41%(95%CI:31%~51%)和38%(95%CI:28%~48%);接种2剂次Salk-IPV后,I、Ⅱ和Ⅲ型脊髓灰质炎病毒中和抗体的SR分别为82%(95%CI:74%~90%)、83%(95%CI:77%~88%)和91%(95%CI:87%~95%)。随着免疫起始月龄推后,无论接种1剂次还是2剂次Salk-IPV,不同血清型脊髓灰质炎病毒中和抗体的SR均呈上升趋势。结论 7岁以下儿童采用二价口服脊髓灰质炎减毒活疫苗和Salk-IPV序贯免疫策略时,建议在常规免疫中至少接种2剂次以上Salk-IPV疫苗,血清中和抗体才有较高的阳性率。
Objective To evaluate the immunogenicity of Salk polio inactivated vaccine (Salk-IPV) administered to children under 7 years of age inoculation with one or two doses of Salk-polio vaccine (Salk-IPV), and to develop appropriate immunizations for the sequential immunization of inactivated polio vaccine (IPV) Program for reference. Methods The studies evaluating the immune effects of Salk-IPV were included in the analysis by searching the NCBI, Cochrane Collaboration Library, CBMdisc, CNKI and Wanfang databases . A meta-analysis of the seroconversion rate (SR) of induced neutralizing antibodies in children <7 years of age after vaccination for at least 1 month described the meta-analysis of the seroconversion rates of seronegative neutralizing antibodies after vaccination with different doses of Salk-IPV The trend of SR. Results A total of 11 articles were included in the meta-analysis. The results of meta-analysis showed that the SR of type I, II and III neutralizing antibodies were 29% (95% CI: 19% -39% ), 41% (95% CI: 31% -51%) and 38% (95% CI: 28% -48%). After inoculation of 2 doses of Salk-IPV, (95% CI: 74% -90%), 83% (95% CI: 77% -88%), and 91% (95% CI: 87% -95%) of the antibody, respectively. The SR of neutralizing antibodies against different serotypes of poliovirus increased with age of 1 month or 2 doses of Salk-IPV. Conclusions When children under 7 years of age are treated with the live attenuated divalent oral poliovirus vaccine and the Salk-IPV sequential immunization strategy, it is recommended that at least two doses of the Salk-IPV vaccine be routinely immunized to have a higher serum neutralizing antibody The positive rate.